Seeking Molecular Markers To Identify Breast Cancer Patients Who Would Benefit Most From Immune Suppressant

A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium. Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer...

Source: http://www.medicalnewstoday.com/releases/244984.php

Katy Perry The Black Keys Cobra Starship DJ Drama